Cannabinoids Data Packaging Therapy 
Cannabis Law Report
SEPTEMBER 15, 2021
Delta-8 THC is one of over 100 cannabinoids produced naturally by the cannabis plant but is not found in significant amounts in the cannabis plant. Some concerns include variability in product formulations and product labeling, other cannabinoid and terpene content, and variable delta-8 THC concentrations. synthetic conversion).
Cannabis Law Report
AUGUST 10, 2021
Dried flower continues to dominate in the Veteran medical cannabis segment, accounting for over 60% of sales according to Canada House’s sales data. Additionally, MTL will leverage the packaging and distribution capabilities of Abba Medix’s fully licensed 20,000 sq. providing approx. 30,000 kilograms of dried flower annually.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Joint Blog
OCTOBER 8, 2021
Even for smaller forms of anxiety such as fear of public speaking, this therapy can be immensely helpful – even reducing symptoms in some participants who experienced relief from their condition after taking 1500mg per day (typically at 10-50mg doses). You can have a look into current CBD studies. .
Cannabis Law Report
JANUARY 9, 2019
Then I saw someone with Stage 4 breast cancer end up in remission from cannabis-based therapy, someone else with skin cancer; kid after kid with seizures all being treated. The biggest pushback Phoenix has received until now has been the lack of data, Tindall said. There seemed so much more to it.”.
CannaMD
MAY 14, 2020
CannaMD has contacted Florida’s leading medical marijuana treatment centers (MMTCs) , who say they’re now just waiting on the Department of Health to issue rules regarding packaging and other essential requirements. Safety of production and packaging. Risks of over-consumption and accidental ingestion.
Puff Puff Post
NOVEMBER 5, 2019
INM-755 is a single-cannabinoid topical cream under development for the treatment of symptoms associated with epidermolysis bullosa (“EB”). With our extensive preclinical development package in hand, we are positioned to efficiently pursue additional indications for INM-755. For more information, visit www.inmedpharma.com.
Puff Puff Post
NOVEMBER 5, 2019
INM-755 is a single-cannabinoid topical cream under development for the treatment of symptoms associated with epidermolysis bullosa (“EB”). With our extensive preclinical development package in hand, we are positioned to efficiently pursue additional indications for INM-755. For more information, visit www.inmedpharma.com.
Expert insights. Personalized for you.
105 
Let's personalize your content